Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats.
Mineralocorticoid effects in the brain include the control of cardiovascular functions, induction of salt appetite, interaction with the vasoactive neuropeptides arginine vasopressin (AVP) and angiotensin II and development or aggravation of hypertension. In this regard, mineralocorticoids may play a pathogenic role in rats with a genetic form of hypertension (spontaneously hypertensive rats, SHR). Our objective was to compare the response of the hypothalamic vasopressinergic system to mineralocorticoid administration in SHR and control Wistar-Kyoto (WKY) rats. Sixteen-week-old male SHR showing a systolic blood pressure of 190 +/- 5 mm Hg and normotensive WKY rats (130 +/- 5 mm Hg) were treated subcutaneously with oil vehicle or a single 10-mg dose of deoxycorticosterone acetate (DOCA). After 2 h, rats were sacrificed and brains prepared for immunocytochemistry of Fos and vasopressin V1a receptor (V1aR) and for non-isotopic in situ hybridization of AVP mRNA. In the basal state, SHR demonstrated a higher number of AVP mRNA- and V1aR-immunopositive cells in the magnocellular division of the paraventricular hypothalamic nucleus (PVN) than WKY rats. After DOCA injection, SHR responded with a significant increase in both parameters with respect to vehicle-injected SHR. In WKY rats, DOCA was without effect on AVP mRNA although it increased the number of V1aR-positive cells. Changes in the number of Fos-positive nuclei were measured in the PVN, median preoptic nucleus (MnPO) and organum vasculosum of the lamina terminalis (OVLT), a circumventricular region showing anatomical connections with the PVN. In vehicle-injected rats, the PVN of SHR showed a higher number of Fos-positive nuclei than in WKY rats, whereas after DOCA treatment, a significant increment occurred in the OVLT but not in the PVN or MnPO of the SHR group only. These data suggest that the enhanced response of the vasopressinergic system to mineralocorticoids may contribute to the abnormal blood pressure of SHR.
Pietranera
Luciana
L
Laboratory of Neuroendocrine Biochemistry, Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina.
Saravia
Flavia
F
Roig
Paulina
P
Lima
Analía
A
De Nicola
Alejandro F
AF
D000818:Animals; D001127:Arginine Vasopressin / Q000187:drug effects / Q000378:metabolism; D003900:Desoxycorticosterone / Q000494:pharmacology; D004195:Disease Models, Animal; D006973:Hypertension / Q000503:physiopathology*; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D008901:Mineralocorticoids / Q000494:pharmacology*; D016761:Oncogene Proteins v-fos / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017483:Receptors, Vasopressin / Q000187:drug effects / Q000378:metabolism; D014667:Vasopressins / Q000187:drug effects* / Q000378:metabolism
D008901:Mineralocorticoids; D016761:Oncogene Proteins v-fos; D012333:RNA, Messenger; D017483:Receptors, Vasopressin; D014667:Vasopressins; D001127:Arginine Vasopressin; D003900:Desoxycorticosterone